I can't remember who suggested this idea earlier tonight,
I can't remember who suggested this idea earlier tonight, but they suggested a scenario with a BP buying out the Lympro test and having the company buy back shares to raise the sp, then uplist with no R/S at all. I doubt it'll happen that way.
I personally wouldn't mind a BP buying Lympro, having the company do a small R/S, then uplist. (short term) Then when the other pipelines come online, have the company do a split, maybe multiple splits as more assets become revenue generating. (Long Term)
Sort of like what happened to AMGN in 90's. Their SP split 5 times in 10 years, and now they currently trade at around $168/share. If you owned just 1,000 shares of AMGN in 1990 it would have ballooned to 48,000 shares by 1999 and would currently be worth over 8 mil today! I can see that happening to us with the awesome pipeline we have.
Very Long AMBS!!
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...
Continue Reading
A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...
Continue Reading
One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...
Continue Reading
November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...
Continue Reading
Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...
Continue Reading
A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...
Continue Reading
December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...
Continue Reading
GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...
Continue Reading
A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...
Continue Reading
A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...
Continue Reading
Top 5 Most Recently Viewed Articles
A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...
Continue Reading
Nebius Secures $700 Million to Accelerate AI Infrastructure Growth Nebius Group N.V. (“Nebius Group”, “Nebius” or the “Company”; NASDAQ:NBIS), a prominent player in AI infrastructure, has made an exciting announcement regarding a substantial private placement financing. In a strategic move to bolster its operations, the company has secured USD 700 million from...
Continue Reading
Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company specializing in neuroscience, has made a significant move by appointing Tucker Kelly as the new Chief Financial Officer (CFO). This decision signals the company's commitment to strategic financial management as it gears up for the commercialization of...
Continue Reading
Brookfield's Bold Ventures into Japan's Real Estate Landscape Canadian investment firm Brookfield Asset Management (TSX: BAM) has recently made headlines with its significant real estate endeavors in Japan, closing two major deals that amount to a staggering $1.6 billion. The Significant Investments Overview The recent acquisitions involve a noteworthy stake in the iconic...
Continue Reading
Legal Proceedings Impacting Pacira BioSciences, Inc. Shareholders of Pacira BioSciences, Inc. should be aware of a significant class action lawsuit that is currently unfolding. This lawsuit, noted for its complexity, aims to address allegations of securities fraud impacting investors. The firm representing the investors, is Levi & Korsinsky, a well-established legal group...
Continue Reading